Sage Therapeutics has faced significant setbacks ... making it the first treatment specifically indicated for postpartum depression (PPD). The next year, Sage signed a major collaboration deal ...

Sage Therapeutics has left its view of Biogen's ... (zuranolone), which is FDA-approved for post-partum depression (PPD). However, its takeover bid has been viewed in some quarters as ...

More than 70% of women prescribed ZURZUVAE are receiving it as their first new treatment for PPD. SAGE-319 is an extrasynaptic-preferring GABAA receptor positive allosteric modulator (PAM ...

Sage Therapeutics, Inc. SAGE reported a loss of $1.01 per share for the first quarter of 2025, wider than the Zacks Consensus ...

Sage Therapeutics is rated a Strong Buy due to ... Sage's Zuranolone shows strong market traction in PPD, with significant insurance coverage and increasing prescriptions, indicating future ...

Sage Therapeutics has said it will cut its headcount ... as the first oral therapy for post-partum depression (PPD), but rejected it for major depressive disorder (MDD), a much larger and more ...

A total of 4 analyst ratings have been received for Sage Therapeutics, with the consensus rating being Neutral. The average one-year price target stands at $9.5, suggesting a potential 21.95% upside.

Sage Therapeutics, Inc. SAGE reported a loss of ... the first and only oral treatment indicated for adults with postpartum depression (PPD), was approved in August 2023 and was commercially ...

--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq ... oral treatment indicated for adults with postpartum depression (PPD). ZURZUVAE was made commercially available in the U.S. in December ...